SuperworthRigel Pharmaceuticals profit margin RIGL
Gross, operating and net profit as a share of revenue over the last twelve months, from 2019.
- Net margin, 12 months
- n/m
- not a meaningful number
- Operating margin, 12 months
- 31.5%
- Peer median
- 22.5%
Rigel Pharmaceuticals' net margin works out at 116% over the last twelve months, but it is not a meaningful number: a margin outside minus 100% to 100% is moved by items that are not sales.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | n/a | 42.6% | 93.3% |
| FY2024 | 9.8% | 13.5% | 89.6% |
| FY2023 | −21.5% | −17.5% | 93.9% |
| FY2022 | −48.7% | −46.2% | 98.5% |
| FY2021 | −12.0% | −8.4% | 99.3% |
| FY2020 | −27.4% | −26.7% | 99.2% |
| FY2019 | n/a | n/a | 98.5% |
| FY2018 | n/a | n/a | n/a |
| FY2017 | n/a | n/a | n/a |
| FY2016 | n/a | n/a | n/a |
| FY2015 | n/a | n/a | n/a |
| FY2014 | n/a | n/a | n/a |
| FY2013 | n/a | n/a | n/a |
| FY2012 | n/a | n/a | n/a |
| FY2011 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | n/a | n/a | 31.5% | |
| Q1 FY26 | n/a | n/a | 41.6% | |
| Q4 FY25 | n/a | n/a | 42.6% | |
| Q3 FY25 | 40.2% | +37.7 pts | 42.2% | |
| Q2 FY25 | 36.5% | +47.4 pts | 39.0% | |
| Q1 FY25 | 18.3% | +34.8 pts | 21.6% | |
| Q4 FY24 | 9.8% | +31.2 pts | 13.5% | |
| Q3 FY24 | 2.5% | +20.9 pts | 6.0% | |
| Q2 FY24 | −10.9% | +18.9 pts | −6.9% | |
| Q1 FY24 | −16.5% | +18.0 pts | −12.2% | |
| Q4 FY23 | −21.5% | +27.2 pts | −17.5% | |
| Q3 FY23 | −18.5% | +74.0 pts | −15.4% |
Against its peers
Companies in Drug Manufacturers - General nearest Rigel Pharmaceuticals' size, closest first, today.
| Company | Profit margin |
|---|---|
| RIGLRigel Pharmaceuticals | n/m |
| ABUSArbutus Biopharma | 84.2% |
| AMPHAmphastar Pharmaceuticals | 10.8% |
| COLLCollegium Pharmaceutical | 5.9% |
| OMEROmeros | n/m |
| CRMDCorMedix | 40.5% |
| ZVRAZevra Therapeutics | 42.8% |
| IRWDIronwood Pharmaceuticals | 33.4% |
| PBYIPuma Biotechnology | 11.6% |
| PCRXPacira BioSciences | 2.0% |
| ANABAnaptysbio | n/m |
| Peer median | 22.5% |
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Rigel Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.